Results 141 to 150 of about 64,512 (289)

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53

Journal of Innate Immunity
Introduction: MDM2 is known as the primary negative regulator of p53, and MDM2 promotes lung cancer fibrosis and lung injury through p53-dependent and p53-independent pathways. However, the mechanism by which MDM2 influences the pathogenesis of asthma is
Su Wang, Shufen Zhong, Ying Huang, Songling Zhu, Shuangfeng Chen, Ran Wang, Sonam Wangmo, Bo Peng, Houkun Lv, Jichao Yang, Liyan Ma, Zhiyang Ling, Yaguang Zhang, Pengfei Sui, Bing Sun   +14 more
doaj   +1 more source

A Nonpeptidic Sulfonamide Inhibits the p53−mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells

, 2016
The evaluation of a sulfonamide inhibitor of the p53−mdm2 interaction is presented. The compound was identified using 3D database searching techniques based on a computationally derived pharmacophore model of mdm2 binding.
Donald J. Abraham (2707078), Peter S. Galatin (2710396)   +1 more
core   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Mdm2: The Ups and Downs [PDF]

Molecular Medicine, 1999
T, Juven-Gershon, M, Oren
openaire   +2 more sources

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Dynamic Changes of ctDNA‐Based MRD and Genomic Mutations Predict Prognosis in ESCC Treated With Definitive Radiotherapy

Cancer Science, EarlyView.
In patients with esophageal squamous cell carcinoma receiving definitive radiotherapy combined with systemic therapy, posttreatment TP53 mutation clearance and ctDNA‐MRD negativity predict favorable outcomes, whereas persistent ctDNA signals indicate elevated relapse risk, supporting nucleosome‐ and MRD‐informed surveillance and risk‐stratification ...
Shutang Liu, Qi Wang, Chun Han, Xiaoning Li, Rutian Cheng, Lihong Liu, Hua Dong, Xuejiao Ren, Shuman Zhen, Lan Wang   +9 more
wiley   +1 more source

Türk popülasyonunda MDM2 SNP309 polimorfizmi [PDF]

, 2017
Amaç: Murine double minute 2 (MDM2) geni p53 tümör süpressör yolağının düzenlenmesinde kritik bir role sahiptir. MDM2, p53 fonksiyonunda büyük bir negatif regülatördür. MDM2 proteini birbirinden bağımsız birçok yolla p53 fonksiyonunu düzenler.
Taş, Ayça, Siliğ, Yavuz, Sari, İsmail, Ağbektaş, Tuğba   +3 more
core